SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENTS FOR LUPUS NEPHRITIS Article Swipe
Ariel Izcovich
,
Fernando Tortosa
,
A Bengolea
,
Mariano Fielli
,
Camila Agnoletti
,
Moira Magdalena Pissinis
,
Martín Ragusa
,
Rosana Quintana
,
Ana Malvar
,
Marina Scolnik
,
Eloísa Bonfá
,
Eduardo Ferreira Borba
,
Odirlei André Monticielo
,
Edgard Torres
,
Loreto Massardo
,
José A. Gómez‐Puerta
,
Carlos Toro
,
Jorge Antonio Esquivel‐Valerio
,
Hilda Fragoso Loyo
,
Juan M. Mejía‐Vilet
,
G S Alarcón
,
Manuel F. Ugarte‐Gil
,
Bernardo A. Pons‐Estel
,
Guillermo Pons‐Estel
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3899/jrheum.2025-0390.pv131
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3899/jrheum.2025-0390.pv131
PV131 / #261 Poster Topic: AS15 - Lupus Nephritis-Clinical Background/Purpose This study aims to evaluate the comparative efficacy and safety of various initial treatments for lupus nephritis through a systematic review and network meta-analysis. Methods A comprehensive literature search was conducted across MEDLINE, EMBASE, Cochrane Library, and LILACS from inception to June 2024 in order to identify randomized controlled trials (RCTs) comparing initial treatments for lupus nephritis. Two reviewers independently performed data extraction and assessed the risk of bias. A frequentist random-effects network meta-analysis was conducted using the restricted maximum likelihood (REML) method to estimate heterogeneity. The certainty of evidence was evaluated using the GRADE approach. Results We included 38 RCTs encompassing 5,146 participants and 11 interventions. Mycophenolate mofetil was selected as the common comparator. The network meta-analysis revealed that voclosporin combined with Mycophenolate mofetil (RR 1.9 95% CI 1.47 to 2.47, RD 281.4, 95% CI 146.3 to 465.4; high certainty) and belimumab combined with Mycophenolate mofetil (RR 1.47, 95% CI 1.23 to 1.74, RD 145, 95% CI 72.7 to 230.9; high certainty) increased complete renal response compared to Mycophenolate mofetil alone. Tacrolimus combined with Mycophenolate mofetil (RR 1.24 95% CI 1.05 to 1.46, RD 113.7, 95% CI 25.2 to 217.7; low certainty) and Obinutuzumab combined with Mycophenolate mofetil (RR 1.57 95% CI 1.05 to 2.34, RD 270.4, 95% CI 22.7 to 640.5; low certainty) also showed potential benefits but with low certainty evidence. Cyclophosphamide was possibly associated with a small decrease in complete renal response compared to Mycophenolate mofetil (RR 0.90, 95% CI 0.77 to 1.04; low certainty). However, the effects of the assessed interventions on mortality and renal replacement therapy outcomes were highly uncertain. Conclusions Combination therapies, particularly voclosporin or belimumab with Mycophenolate mofetil, may provide enhanced outcomes for lupus nephritis initial treatment. Given the complexity of lupus nephritis, clinicians should weigh these findings alongside considerations such as drug availability, cost, and individual patient preferences to guide treatment decisions.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3899/jrheum.2025-0390.pv131
- https://www.jrheum.org/content/jrheum/52/Suppl_1/156.1.full.pdf
- OA Status
- bronze
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4410512994
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4410512994Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3899/jrheum.2025-0390.pv131Digital Object Identifier
- Title
-
SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENTS FOR LUPUS NEPHRITISWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-05-20Full publication date if available
- Authors
-
Ariel Izcovich, Fernando Tortosa, A Bengolea, Mariano Fielli, Camila Agnoletti, Moira Magdalena Pissinis, Martín Ragusa, Rosana Quintana, Ana Malvar, Marina Scolnik, Eloísa Bonfá, Eduardo Ferreira Borba, Odirlei André Monticielo, Edgard Torres, Loreto Massardo, José A. Gómez‐Puerta, Carlos Toro, Jorge Antonio Esquivel‐Valerio, Hilda Fragoso Loyo, Juan M. Mejía‐Vilet, G S Alarcón, Manuel F. Ugarte‐Gil, Bernardo A. Pons‐Estel, Guillermo Pons‐EstelList of authors in order
- Landing page
-
https://doi.org/10.3899/jrheum.2025-0390.pv131Publisher landing page
- PDF URL
-
https://www.jrheum.org/content/jrheum/52/Suppl_1/156.1.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://www.jrheum.org/content/jrheum/52/Suppl_1/156.1.full.pdfDirect OA link when available
- Concepts
-
Medicine, Lupus nephritis, Meta-analysis, Systemic lupus erythematosus, MEDLINE, Dermatology, Internal medicine, Immunology, Disease, Political science, LawTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4410512994 |
|---|---|
| doi | https://doi.org/10.3899/jrheum.2025-0390.pv131 |
| ids.doi | https://doi.org/10.3899/jrheum.2025-0390.pv131 |
| ids.openalex | https://openalex.org/W4410512994 |
| fwci | 0.0 |
| type | article |
| title | SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENTS FOR LUPUS NEPHRITIS |
| biblio.issue | Suppl 1 |
| biblio.volume | 52 |
| biblio.last_page | 156 |
| biblio.first_page | 156.1 |
| topics[0].id | https://openalex.org/T10308 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9739000201225281 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2745 |
| topics[0].subfield.display_name | Rheumatology |
| topics[0].display_name | Systemic Lupus Erythematosus Research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9513803720474243 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2779912601 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8806861639022827 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1621830 |
| concepts[1].display_name | Lupus nephritis |
| concepts[2].id | https://openalex.org/C95190672 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7148057818412781 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q815382 |
| concepts[2].display_name | Meta-analysis |
| concepts[3].id | https://openalex.org/C2776912625 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5533398389816284 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1485 |
| concepts[3].display_name | Systemic lupus erythematosus |
| concepts[4].id | https://openalex.org/C2779473830 |
| concepts[4].level | 2 |
| concepts[4].score | 0.4445287585258484 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1540899 |
| concepts[4].display_name | MEDLINE |
| concepts[5].id | https://openalex.org/C16005928 |
| concepts[5].level | 1 |
| concepts[5].score | 0.4021034240722656 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q171171 |
| concepts[5].display_name | Dermatology |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.3597269356250763 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C203014093 |
| concepts[7].level | 1 |
| concepts[7].score | 0.35228145122528076 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[7].display_name | Immunology |
| concepts[8].id | https://openalex.org/C2779134260 |
| concepts[8].level | 2 |
| concepts[8].score | 0.0868426263332367 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[8].display_name | Disease |
| concepts[9].id | https://openalex.org/C17744445 |
| concepts[9].level | 0 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q36442 |
| concepts[9].display_name | Political science |
| concepts[10].id | https://openalex.org/C199539241 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q7748 |
| concepts[10].display_name | Law |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9513803720474243 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/lupus-nephritis |
| keywords[1].score | 0.8806861639022827 |
| keywords[1].display_name | Lupus nephritis |
| keywords[2].id | https://openalex.org/keywords/meta-analysis |
| keywords[2].score | 0.7148057818412781 |
| keywords[2].display_name | Meta-analysis |
| keywords[3].id | https://openalex.org/keywords/systemic-lupus-erythematosus |
| keywords[3].score | 0.5533398389816284 |
| keywords[3].display_name | Systemic lupus erythematosus |
| keywords[4].id | https://openalex.org/keywords/medline |
| keywords[4].score | 0.4445287585258484 |
| keywords[4].display_name | MEDLINE |
| keywords[5].id | https://openalex.org/keywords/dermatology |
| keywords[5].score | 0.4021034240722656 |
| keywords[5].display_name | Dermatology |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.3597269356250763 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/immunology |
| keywords[7].score | 0.35228145122528076 |
| keywords[7].display_name | Immunology |
| keywords[8].id | https://openalex.org/keywords/disease |
| keywords[8].score | 0.0868426263332367 |
| keywords[8].display_name | Disease |
| language | en |
| locations[0].id | doi:10.3899/jrheum.2025-0390.pv131 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S50602745 |
| locations[0].source.issn | 0315-162X, 1499-2752 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0315-162X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | The Journal of Rheumatology |
| locations[0].source.host_organization | https://openalex.org/P4310320417 |
| locations[0].source.host_organization_name | The Journal of Rheumatology Publishing Company Limited |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320417 |
| locations[0].source.host_organization_lineage_names | The Journal of Rheumatology Publishing Company Limited |
| locations[0].license | |
| locations[0].pdf_url | https://www.jrheum.org/content/jrheum/52/Suppl_1/156.1.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | The Journal of Rheumatology |
| locations[0].landing_page_url | https://doi.org/10.3899/jrheum.2025-0390.pv131 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5028653674 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9053-4396 |
| authorships[0].author.display_name | Ariel Izcovich |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Ariel Izcovich |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5002842430 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-0303-6055 |
| authorships[1].author.display_name | Fernando Tortosa |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Fernando Tortosa |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5017829420 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-5741-5221 |
| authorships[2].author.display_name | A Bengolea |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Agustin Bengolea |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5086318646 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Mariano Fielli |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mariano Fielli |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5051957248 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5995-9097 |
| authorships[4].author.display_name | Camila Agnoletti |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Camila Agnoletti |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5071518175 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Moira Magdalena Pissinis |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Moira Magdalena Pissinis |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5056220203 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-3182-8041 |
| authorships[6].author.display_name | Martín Ragusa |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Martín Ragusa |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5060072103 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-0643-2755 |
| authorships[7].author.display_name | Rosana Quintana |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Rosana Quintana |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5022937823 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-1609-3857 |
| authorships[8].author.display_name | Ana Malvar |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Ana Malvar |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5011290004 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-0542-8001 |
| authorships[9].author.display_name | Marina Scolnik |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Marina Scolnik |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5065178869 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-0520-4681 |
| authorships[10].author.display_name | Eloísa Bonfá |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Eloisa Bonfá |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5063331299 |
| authorships[11].author.orcid | https://orcid.org/0000-0001-6194-5129 |
| authorships[11].author.display_name | Eduardo Ferreira Borba |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Eduardo F. Borba |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5052386622 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-0720-2097 |
| authorships[12].author.display_name | Odirlei André Monticielo |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Odirlei Andre Monticielo |
| authorships[12].is_corresponding | False |
| authorships[13].author.id | https://openalex.org/A5085991706 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | Edgard Torres |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Edgard Torres |
| authorships[13].is_corresponding | False |
| authorships[14].author.id | https://openalex.org/A5013179170 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-4790-1258 |
| authorships[14].author.display_name | Loreto Massardo |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Loreto Massardo |
| authorships[14].is_corresponding | False |
| authorships[15].author.id | https://openalex.org/A5008861132 |
| authorships[15].author.orcid | https://orcid.org/0000-0001-8177-702X |
| authorships[15].author.display_name | José A. Gómez‐Puerta |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | José Gómez-Puerta |
| authorships[15].is_corresponding | False |
| authorships[16].author.id | https://openalex.org/A5103551700 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | Carlos Toro |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Carlos Toro |
| authorships[16].is_corresponding | False |
| authorships[17].author.id | https://openalex.org/A5042673785 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-3124-0395 |
| authorships[17].author.display_name | Jorge Antonio Esquivel‐Valerio |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Jorge A. Esquivel-Valerio |
| authorships[17].is_corresponding | False |
| authorships[18].author.id | https://openalex.org/A5006818760 |
| authorships[18].author.orcid | |
| authorships[18].author.display_name | Hilda Fragoso Loyo |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Hilda Fragoso Loyo |
| authorships[18].is_corresponding | False |
| authorships[19].author.id | https://openalex.org/A5004615717 |
| authorships[19].author.orcid | https://orcid.org/0000-0003-4062-9412 |
| authorships[19].author.display_name | Juan M. Mejía‐Vilet |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Juan Manuel Mejia-Vilet |
| authorships[19].is_corresponding | False |
| authorships[20].author.id | https://openalex.org/A5110563987 |
| authorships[20].author.orcid | |
| authorships[20].author.display_name | G S Alarcón |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Graciela S. Alarcón |
| authorships[20].is_corresponding | False |
| authorships[21].author.id | https://openalex.org/A5030859731 |
| authorships[21].author.orcid | https://orcid.org/0000-0003-1728-1999 |
| authorships[21].author.display_name | Manuel F. Ugarte‐Gil |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Manuel Francisco Ugarte-Gil |
| authorships[21].is_corresponding | False |
| authorships[22].author.id | https://openalex.org/A5060842182 |
| authorships[22].author.orcid | https://orcid.org/0000-0003-2518-0266 |
| authorships[22].author.display_name | Bernardo A. Pons‐Estel |
| authorships[22].author_position | middle |
| authorships[22].raw_author_name | Bernardo A. Pons-Estel |
| authorships[22].is_corresponding | False |
| authorships[23].author.id | https://openalex.org/A5029153882 |
| authorships[23].author.orcid | https://orcid.org/0000-0002-0647-929X |
| authorships[23].author.display_name | Guillermo Pons‐Estel |
| authorships[23].author_position | last |
| authorships[23].raw_author_name | Guillermo Pons-Estel |
| authorships[23].is_corresponding | False |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.jrheum.org/content/jrheum/52/Suppl_1/156.1.full.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENTS FOR LUPUS NEPHRITIS |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10308 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9739000201225281 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2745 |
| primary_topic.subfield.display_name | Rheumatology |
| primary_topic.display_name | Systemic Lupus Erythematosus Research |
| related_works | https://openalex.org/W2098134050, https://openalex.org/W2776803289, https://openalex.org/W2778847013, https://openalex.org/W2364717911, https://openalex.org/W3166910253, https://openalex.org/W2591530766, https://openalex.org/W2951958669, https://openalex.org/W3214891379, https://openalex.org/W2177092523, https://openalex.org/W2804688660 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.3899/jrheum.2025-0390.pv131 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S50602745 |
| best_oa_location.source.issn | 0315-162X, 1499-2752 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0315-162X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | The Journal of Rheumatology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320417 |
| best_oa_location.source.host_organization_name | The Journal of Rheumatology Publishing Company Limited |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320417 |
| best_oa_location.source.host_organization_lineage_names | The Journal of Rheumatology Publishing Company Limited |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://www.jrheum.org/content/jrheum/52/Suppl_1/156.1.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | The Journal of Rheumatology |
| best_oa_location.landing_page_url | https://doi.org/10.3899/jrheum.2025-0390.pv131 |
| primary_location.id | doi:10.3899/jrheum.2025-0390.pv131 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S50602745 |
| primary_location.source.issn | 0315-162X, 1499-2752 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0315-162X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | The Journal of Rheumatology |
| primary_location.source.host_organization | https://openalex.org/P4310320417 |
| primary_location.source.host_organization_name | The Journal of Rheumatology Publishing Company Limited |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320417 |
| primary_location.source.host_organization_lineage_names | The Journal of Rheumatology Publishing Company Limited |
| primary_location.license | |
| primary_location.pdf_url | https://www.jrheum.org/content/jrheum/52/Suppl_1/156.1.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | The Journal of Rheumatology |
| primary_location.landing_page_url | https://doi.org/10.3899/jrheum.2025-0390.pv131 |
| publication_date | 2025-05-20 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.- | 6 |
| abstract_inverted_index./ | 1 |
| abstract_inverted_index.A | 35, 79 |
| abstract_inverted_index.a | 28, 239 |
| abstract_inverted_index.11 | 115 |
| abstract_inverted_index.38 | 109 |
| abstract_inverted_index.CI | 138, 145, 160, 167, 190, 197, 212, 219, 253 |
| abstract_inverted_index.RD | 142, 164, 194, 216 |
| abstract_inverted_index.We | 107 |
| abstract_inverted_index.as | 121, 309 |
| abstract_inverted_index.in | 53, 242 |
| abstract_inverted_index.of | 20, 77, 98, 262, 298 |
| abstract_inverted_index.on | 266 |
| abstract_inverted_index.or | 281 |
| abstract_inverted_index.to | 13, 50, 55, 93, 140, 147, 162, 169, 178, 192, 199, 214, 221, 247, 255, 317 |
| abstract_inverted_index.(RR | 135, 157, 187, 209, 250 |
| abstract_inverted_index.1.9 | 136 |
| abstract_inverted_index.95% | 137, 144, 159, 166, 189, 196, 211, 218, 252 |
| abstract_inverted_index.The | 96, 125 |
| abstract_inverted_index.Two | 67 |
| abstract_inverted_index.and | 18, 31, 46, 73, 114, 151, 203, 268, 313 |
| abstract_inverted_index.but | 229 |
| abstract_inverted_index.for | 24, 64, 290 |
| abstract_inverted_index.low | 201, 223, 231, 257 |
| abstract_inverted_index.may | 286 |
| abstract_inverted_index.the | 15, 75, 87, 103, 122, 260, 263, 296 |
| abstract_inverted_index.was | 39, 84, 100, 119, 235 |
| abstract_inverted_index.#261 | 2 |
| abstract_inverted_index.0.77 | 254 |
| abstract_inverted_index.1.05 | 191, 213 |
| abstract_inverted_index.1.23 | 161 |
| abstract_inverted_index.1.24 | 188 |
| abstract_inverted_index.1.47 | 139 |
| abstract_inverted_index.1.57 | 210 |
| abstract_inverted_index.145, | 165 |
| abstract_inverted_index.2024 | 52 |
| abstract_inverted_index.22.7 | 220 |
| abstract_inverted_index.25.2 | 198 |
| abstract_inverted_index.72.7 | 168 |
| abstract_inverted_index.AS15 | 5 |
| abstract_inverted_index.June | 51 |
| abstract_inverted_index.RCTs | 110 |
| abstract_inverted_index.This | 10 |
| abstract_inverted_index.aims | 12 |
| abstract_inverted_index.also | 225 |
| abstract_inverted_index.data | 71 |
| abstract_inverted_index.drug | 310 |
| abstract_inverted_index.from | 48 |
| abstract_inverted_index.high | 149, 171 |
| abstract_inverted_index.risk | 76 |
| abstract_inverted_index.such | 308 |
| abstract_inverted_index.that | 129 |
| abstract_inverted_index.were | 273 |
| abstract_inverted_index.with | 132, 154, 184, 206, 230, 238, 283 |
| abstract_inverted_index.0.90, | 251 |
| abstract_inverted_index.1.04; | 256 |
| abstract_inverted_index.1.46, | 193 |
| abstract_inverted_index.1.47, | 158 |
| abstract_inverted_index.1.74, | 163 |
| abstract_inverted_index.146.3 | 146 |
| abstract_inverted_index.2.34, | 215 |
| abstract_inverted_index.2.47, | 141 |
| abstract_inverted_index.5,146 | 112 |
| abstract_inverted_index.GRADE | 104 |
| abstract_inverted_index.Given | 295 |
| abstract_inverted_index.Lupus | 7 |
| abstract_inverted_index.PV131 | 0 |
| abstract_inverted_index.bias. | 78 |
| abstract_inverted_index.cost, | 312 |
| abstract_inverted_index.guide | 318 |
| abstract_inverted_index.lupus | 25, 65, 291, 299 |
| abstract_inverted_index.order | 54 |
| abstract_inverted_index.renal | 175, 244, 269 |
| abstract_inverted_index.small | 240 |
| abstract_inverted_index.study | 11 |
| abstract_inverted_index.these | 304 |
| abstract_inverted_index.using | 86, 102 |
| abstract_inverted_index.weigh | 303 |
| abstract_inverted_index.(RCTs) | 60 |
| abstract_inverted_index.(REML) | 91 |
| abstract_inverted_index.113.7, | 195 |
| abstract_inverted_index.217.7; | 200 |
| abstract_inverted_index.230.9; | 170 |
| abstract_inverted_index.270.4, | 217 |
| abstract_inverted_index.281.4, | 143 |
| abstract_inverted_index.465.4; | 148 |
| abstract_inverted_index.640.5; | 222 |
| abstract_inverted_index.LILACS | 47 |
| abstract_inverted_index.Poster | 3 |
| abstract_inverted_index.Topic: | 4 |
| abstract_inverted_index.across | 41 |
| abstract_inverted_index.alone. | 181 |
| abstract_inverted_index.common | 123 |
| abstract_inverted_index.highly | 274 |
| abstract_inverted_index.method | 92 |
| abstract_inverted_index.review | 30 |
| abstract_inverted_index.safety | 19 |
| abstract_inverted_index.search | 38 |
| abstract_inverted_index.should | 302 |
| abstract_inverted_index.showed | 226 |
| abstract_inverted_index.trials | 59 |
| abstract_inverted_index.EMBASE, | 43 |
| abstract_inverted_index.Methods | 34 |
| abstract_inverted_index.Results | 106 |
| abstract_inverted_index.effects | 261 |
| abstract_inverted_index.initial | 22, 62, 293 |
| abstract_inverted_index.maximum | 89 |
| abstract_inverted_index.mofetil | 118, 134, 156, 180, 186, 208, 249 |
| abstract_inverted_index.network | 32, 82, 126 |
| abstract_inverted_index.patient | 315 |
| abstract_inverted_index.provide | 287 |
| abstract_inverted_index.therapy | 271 |
| abstract_inverted_index.through | 27 |
| abstract_inverted_index.various | 21 |
| abstract_inverted_index.Cochrane | 44 |
| abstract_inverted_index.However, | 259 |
| abstract_inverted_index.Library, | 45 |
| abstract_inverted_index.MEDLINE, | 42 |
| abstract_inverted_index.assessed | 74, 264 |
| abstract_inverted_index.benefits | 228 |
| abstract_inverted_index.combined | 131, 153, 183, 205 |
| abstract_inverted_index.compared | 177, 246 |
| abstract_inverted_index.complete | 174, 243 |
| abstract_inverted_index.decrease | 241 |
| abstract_inverted_index.efficacy | 17 |
| abstract_inverted_index.enhanced | 288 |
| abstract_inverted_index.estimate | 94 |
| abstract_inverted_index.evaluate | 14 |
| abstract_inverted_index.evidence | 99 |
| abstract_inverted_index.findings | 305 |
| abstract_inverted_index.identify | 56 |
| abstract_inverted_index.included | 108 |
| abstract_inverted_index.mofetil, | 285 |
| abstract_inverted_index.outcomes | 272, 289 |
| abstract_inverted_index.possibly | 236 |
| abstract_inverted_index.response | 176, 245 |
| abstract_inverted_index.revealed | 128 |
| abstract_inverted_index.selected | 120 |
| abstract_inverted_index.alongside | 306 |
| abstract_inverted_index.approach. | 105 |
| abstract_inverted_index.belimumab | 152, 282 |
| abstract_inverted_index.certainty | 97, 232 |
| abstract_inverted_index.comparing | 61 |
| abstract_inverted_index.conducted | 40, 85 |
| abstract_inverted_index.evaluated | 101 |
| abstract_inverted_index.evidence. | 233 |
| abstract_inverted_index.inception | 49 |
| abstract_inverted_index.increased | 173 |
| abstract_inverted_index.mortality | 267 |
| abstract_inverted_index.nephritis | 26, 292 |
| abstract_inverted_index.performed | 70 |
| abstract_inverted_index.potential | 227 |
| abstract_inverted_index.reviewers | 68 |
| abstract_inverted_index.treatment | 319 |
| abstract_inverted_index.Tacrolimus | 182 |
| abstract_inverted_index.associated | 237 |
| abstract_inverted_index.certainty) | 150, 172, 202, 224 |
| abstract_inverted_index.clinicians | 301 |
| abstract_inverted_index.complexity | 297 |
| abstract_inverted_index.controlled | 58 |
| abstract_inverted_index.decisions. | 320 |
| abstract_inverted_index.extraction | 72 |
| abstract_inverted_index.individual | 314 |
| abstract_inverted_index.likelihood | 90 |
| abstract_inverted_index.literature | 37 |
| abstract_inverted_index.nephritis, | 300 |
| abstract_inverted_index.nephritis. | 66 |
| abstract_inverted_index.randomized | 57 |
| abstract_inverted_index.restricted | 88 |
| abstract_inverted_index.systematic | 29 |
| abstract_inverted_index.therapies, | 278 |
| abstract_inverted_index.treatment. | 294 |
| abstract_inverted_index.treatments | 23, 63 |
| abstract_inverted_index.uncertain. | 275 |
| abstract_inverted_index.Combination | 277 |
| abstract_inverted_index.Conclusions | 276 |
| abstract_inverted_index.certainty). | 258 |
| abstract_inverted_index.comparative | 16 |
| abstract_inverted_index.comparator. | 124 |
| abstract_inverted_index.frequentist | 80 |
| abstract_inverted_index.preferences | 316 |
| abstract_inverted_index.replacement | 270 |
| abstract_inverted_index.voclosporin | 130, 280 |
| abstract_inverted_index.Obinutuzumab | 204 |
| abstract_inverted_index.encompassing | 111 |
| abstract_inverted_index.participants | 113 |
| abstract_inverted_index.particularly | 279 |
| abstract_inverted_index.Mycophenolate | 117, 133, 155, 179, 185, 207, 248, 284 |
| abstract_inverted_index.availability, | 311 |
| abstract_inverted_index.comprehensive | 36 |
| abstract_inverted_index.independently | 69 |
| abstract_inverted_index.interventions | 265 |
| abstract_inverted_index.meta-analysis | 83, 127 |
| abstract_inverted_index.considerations | 307 |
| abstract_inverted_index.heterogeneity. | 95 |
| abstract_inverted_index.interventions. | 116 |
| abstract_inverted_index.meta-analysis. | 33 |
| abstract_inverted_index.random-effects | 81 |
| abstract_inverted_index.Cyclophosphamide | 234 |
| abstract_inverted_index.Background/Purpose | 9 |
| abstract_inverted_index.Nephritis-Clinical | 8 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 24 |
| citation_normalized_percentile.value | 0.26456098 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |